Screener
Kura Oncology KURA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | 3,778 | 46 |
| Other long-term liabilities | 204 | 259 |
| Contract liabilities | (9,443) | 34,594 |
| Net cash used in operating activities | (85,854) | (71,927) |
| Investing Activities | ||
| Purchases of short-term investments | (171,601) | (268,714) |
| Maturities of short-term investments | 147,498 | 167,597 |
| Purchases of property and equipment | (128) | (292) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's operating cash flow?
- Kura Oncology (KURA) reported operating cash flow of -$85.85M in Q1 2026.
- How has Kura Oncology's operating cash flow changed year-over-year?
- Kura Oncology's operating cash flow decreased by 19.4% year-over-year, from -$71.93M to -$85.85M.
- What is the long-term trend for Kura Oncology's operating cash flow?
- Over 3 years (2021 to 2024), Kura Oncology's operating cash flow has grown at a 8.7% compound annual growth rate (CAGR), from -$104.55M to $134.32M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Kura Oncology's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude